A Phase 2 trial of AI-071 for immune related adverse events
Latest Information Update: 03 Oct 2024
At a glance
- Drugs AI 071 (Primary)
- Indications Cancer
- Focus Adverse reactions
- 03 Oct 2024 New trial record
- 25 Sep 2024 According to an OncoC4 media release, initiation of Phase 2 trial for immune related adverse events expected in Q1 2025.